Drug Approval | December 06, 2024
FDA accepts supplemental Biologics License Application for Roche’s Columvi combination
For people with relapsed or refractory diffuse large B-cell lymphoma
For people with relapsed or refractory diffuse large B-cell lymphoma
Akums Drugs will undertake this development and commercialization in India
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
This license will enable Abbott to enhance access to this novel therapy to more patients across India
Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)
PEKK is a high-performance polymer family used in aerospace and other demanding markets
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Subscribe To Our Newsletter & Stay Updated
